December 09, 2021
Report: Tecfidera, Aubagio Preferred RRMS Treatments in Canada
From: Multiple Sclerosis News Today
Tecfidera (dimethyl fumarate) and Aubagio (teriflunomide) are the preferred disease-modifying treatments for managing relapsing-remitting multiple sclerosis (RRMS) in Canada, according to a report from Spherix Global Insights.
The report was part of Spherix’s RealTime Dynamix: Multiple Sclerosis (Canada) service, which collects data on market trends of MS treatments in Canada by surveying healthcare providers in the country. This most recent report is based on responses from 47 MS specialists and neurologists, given in October and early November.
The preference for Tecfidera and Aubagio as a first-line RRMS treatment, “is easily seen in the strong reliance on these brands for first-line RRMS prescribing, especially among patients presenting without concerning prognostic profiles,” according to a press release from Spherix… (read more)